India markets closed
  • BSE SENSEX

    48,878.54
    -746.22 (-1.50%)
     
  • Nifty 50

    14,371.90
    -218.45 (-1.50%)
     
  • USD/INR

    72.9740
    +0.0240 (+0.03%)
     
  • Dow

    30,940.57
    -235.44 (-0.76%)
     
  • Nasdaq

    13,477.86
    -53.06 (-0.39%)
     
  • BTC-INR

    2,363,016.00
    +139,070.00 (+6.25%)
     
  • CMC Crypto 200

    643.39
    +33.40 (+5.48%)
     
  • Hang Seng

    29,447.85
    -479.91 (-1.60%)
     
  • Nikkei

    28,631.45
    -125.41 (-0.44%)
     
  • EUR/INR

    88.8407
    +0.0460 (+0.05%)
     
  • GBP/INR

    99.6743
    -0.4912 (-0.49%)
     
  • AED/INR

    19.8230
    +0.0070 (+0.04%)
     
  • INR/JPY

    1.4198
    +0.0037 (+0.26%)
     
  • SGD/INR

    54.9710
    -0.1950 (-0.35%)
     

The Law Offices of Frank R. Cruz Announces Investigation of Fortress Biotech, Inc. (FBIO) on Behalf of Investors

·2-min read

The Law Offices of Frank R. Cruz announces an investigation of Fortress Biotech, Inc. ("Fortress" or the "Company") (NASDAQ: FBIO) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

Fortress develops and commercializes pharmaceutical and biotechnology products. In December 2019, the Company's majority-controlled subsidiary, Avenue Therapeutics, Inc. ("Avenue"), submitted a New Drug Application ("NDA") for its intravenous ("IV") Tramadol product to the U.S. Food and Drug Administration ("FDA") for the management of moderate to moderately severe pain in adults in a medically supervised health care setting.

On October 12, 2020, Avenue disclosed receipt of a Complete Response Letter ("CRL") from the FDA regarding the NDA for its IV Tramadol product. Specifically, the FDA advised Avenue that "it cannot approve the application in its present form" because "IV tramadol, intended to treat patients in acute pain who require an opioid, is not safe for the intended patient population." Specifically, the CRL stated: "[I]f a patient requires an analgesic between the first dose of IV tramadol and the onset of analgesia, a rescue analgesic would be needed. The likely choice would be another opioid, which would result in opioid 'stacking' and increase the likelihood of opioid-related adverse effects."

On this news, Fortress's stock price fell $1.00 per share, or 23.98%, to close at $3.17 per share on October 12, 2020, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Fortress securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201203005299/en/

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com